About Demeetra
Demeetra is a genome engineering company focused on helping biopharmaceutical innovators build better cell lines with greater precision, flexibility, and control.
Founded in 2019 and headquartered in Lexington, Kentucky, Demeetra develops advanced genome engineering platforms and integrated services designed to accelerate cell line development, biomanufacturing, and discovery programs, without locking partners into rigid, long-term commercialization pathways.
Why We Exist
Demeetra was built to change that.
What We Do
Our core technologies include:
- Cas-CLOVER, a highly precise dimeric nuclease alternative to CRISPR/Cas9, designed to support a clearer path to commercial freedom-to-operate.
- Harbor-IN, a proprietary high-performance transposase enabling stable gene integration
- CleanCut CHO host cell lines, engineered to support consistent, high-quality biologics production
- Super piggyBac, a hyperactive protein-engineered transposase optimized for high-activity multicopy integration, particularly in difficult-to-engineer cell types
- Integrated CLD with Coordinated GMP Manufacturing connects cell line development (CLD) directly to upstream process development and GMP manufacturing, without rebuilds, relicensing, or vendor handoff delays.
How We’re Different
Demeetra operates with an intentionally flexible engagement model.
We offer platform access through licensing and integrated cell line development services, allowing partners to choose the level of support that fits their strategy.
This approach gives teams access to advanced genome engineering technologies and production-ready host cells, while avoiding long-term, single-provider commercialization constraints.
By combining open platform access with deep technical execution, Demeetra helps reduce development risk, preserve strategic optionality, and advance high-quality biologics more efficiently.
